Inclusion of Moderate-to-Severe Ezcema under Chronic Disease Management Programme

Assoc Prof Jamus Jerome Lim asked the Coordinating Minister for Social Policies and Minister for Health whether the Ministry will consider including moderate-to-severe eczema under the Chronic Disease Management Programme.

Conditions under the Chronic Disease Management Programme (CDMP) are regularly reviewed by a Clinical Advisory Committee (CAC), comprising family physicians and specialists from the public and private sectors. In assessing the inclusion of conditions onto the CDMP, the CAC consults clinical experts in various healthcare settings, and considers factors such as disease burden, potential benefits of early interventions to patient outcomes, the cumulative cost to the patient from long-term treatment, and the availability of evidence-based clinical guidelines for appropriate care of the condition.

Eczema will be assessed for inclusion into the CDMP.

Even though eczema is currently not on the CDMP, patients can already access subsidised treatments for eczema today. Eligible patients may receive subsidies of up to 75% at polyclinics and specialist outpatient Clinics for their eczema treatment and medications. Patients aged 60 years and above can also tap on Flexi-MediSave to pay for eczema treatments and medications, up to the prevailing withdrawal limit.